硫化氢供体对Apo E基因敲除小鼠动脉粥样硬化的调节作用

目的探讨硫化氢(H2S)供体对Apo E基因敲除小鼠(Apo E-/-)动脉粥样硬化的调节作用。方法6wk龄正常C57BL/6J和Apo E-/-小鼠分为正常对照组、ApoE-/-组和Apo E-/-+硫氢化钠(NaHS)组,每组各8只,普通饮食饲养至16wk龄。分别观察各组小鼠血清中总胆固醇(TCHO)、低密度脂蛋白(LDL-C)和高密度脂蛋白(HDL-C)含量及主动脉根部斑块面积的变化;用硫电极法测定血清中H2S的含量。结果与对照组相比,Apo E-/-小鼠血清中TCHO[(12.59±3.11vs2.32±0.40)μmol·L-1]和LDL-C[(1.33±0.43vs0.13±0.03)μmol·L-1]水平明显升高,而HDL-C水平[(0.45±0.13vs1.49±0.21)μmol·L-1]明显降低,血清中H2S的含量[(44.64±4.52)μmol·L-1]较对照组[(57.69±7.03)μmol·L-1]明显下降,主动脉根部明显出现斑块[(139316.6±30362.93vs0)μm2];给予NaHS后,Apo E-/-小鼠血清中TCHO、LDL-C和HDL-C水平无明显变化,而血清中H2S的含量明显升高[(52.21±7.24vs44.64±4.52)μmol·L-1],主动脉根部动脉粥样硬化斑块明显缩小[(85927.84±1922.73vs139316.6±30362.93)μm2]。结论新型气体信号分子H2S可以延缓动脉粥样硬化的进程,缩小动脉粥样硬化斑块形成。     

超敏C反应蛋白和低密度脂蛋白胆固醇对脑梗死患者颈动脉粥样硬化斑块性质的预测意义

目的观察超敏C-反应蛋白(hs-CRP)和低密度脂蛋白胆固醇(LDL-C)与脑梗死患者颈动脉粥样硬化斑块之间的关系。方法收集161例存在颈动脉粥样硬化斑块的脑梗死患者的颈动脉彩超结果,根据斑块情况分为易损斑块组(58例),稳定斑块组(73例),对照组(30例),收集患者血中hs-CRP及LDL-C的数值。结果 LDL-C水平:易损斑块组(3.65±1.71mmol/l)>稳定斑块组(3.13±1.06mmol/l)>对照组(2.71±0.13mmol/l),三组间差异无统计学意义(P>0.05);hs-CRP水平:易损斑块组[2.39(1.24,19.3)mmol/l]>稳定斑块组[1.96(1.01,9.3)mmol/l]>对照组[0.88(0.02,3.1)mmol/l],三组间差异有统计学意义(P<001);二者之间呈正相关(r=0.249,P<0.05)。结论 hs-CRP在易损斑块组明显高于稳定斑块组及对照组,它在一定程度上可以预测动脉粥样硬化斑块的性质,而LDL-C水平与斑块性质之间无明显关系。     

硫酸甘糖酯对鹌鹑实验性动脉粥样损害的影响(英文)

雄性鹌鹑用高脂饲料喂养8wk能形成典型的高脂血症和动脉粥样硬化斑块,给动物po硫酸苷糖酯(PGMS)50及25 mg·kg~1·d~1,能明显抑制鹌鹑血清总胆固醇TC及(LDL+VLDL)C水平的升高,提高HDL C/TC及HDL_2/HDL_3 C比值,实验8 wk末,高脂组动脉病变重,斑块发生率为91.7％(11/12);PGMS高,低剂量组动脉病变轻,斑块发生率分别为25.0％(3/12)及41.7％(5/12).光镜和电镜观察表明,用药组动脉内膜增生明显轻于高脂组,提示硫酸甘糖酯对平滑肌细胞的增生具有抑制作用,并能延缓动脉粥样硬化的发生和发展。     

硝苯地平对慢性铁过负荷大鼠铁沉积和营养代谢的影响

目的观察硝苯地平对慢性铁过负荷大鼠肝、肾和脾组织铁沉积与营养代谢的影响,探讨硝苯地平治疗铁过负荷等代谢疾病的可能性。方法雄性SD大鼠连续8周喂饲铁含量为3.5 g.kg-1的高铁饲料,制备慢性铁过负荷动物模型。8周后,模型大鼠ip给予硝苯地平1,3和5 mg.kg-1,连续7 d。组织学染色观察肝、肾和脾组织铁沉积,用试剂盒分别测定血脂、脂质过氧化及抗氧化指标,同时测定血清铁蛋白(SF)和总铁结合力(TIBC);用全自动生化分析仪或荧光分光光度计检测血清中营养元素铁、钙、锌和硒的含量。结果与正常对照组比较,慢性铁过负荷模型组大鼠肝、肾和脾组织中铁沉积明显;与模型组比较,硝苯地平5 mg.kg-1组组织中铁沉积明显降低(P<0.05,P<0.01)。与正常对照组比较,模型组血清甘油三酯(TG)含量由1.25±0.21升高到(1.86±0.75)mmol.L-1,总胆固醇(TC)由1.52±0.17升高到(1.91±0.34)mmol.L-1,丙二醛(MDA)由11.2±2.8升高到(15.3±3.6)μmol.L-1,谷胱甘肽过氧化物酶(GSH-Px)活性由204±52升高到(286±75)kU.L-1(P<0.05),高密度脂蛋白(HDL)、低密度脂蛋白(LDL)含量和超氧化物歧化酶(SOD)活性无明显变化;与模型组比较,硝苯地平5 mg.kg-1组TC降低到(1.65±0.36)mmol.L-1,LDL由1.14±0.15降低到(0.86±0.16)mmol.L-1,MDA含量降低到(11.9±3.5)μmol.L-1(P<0.05),TG,HDL,SOD和GSH-Px无明显变化;硝苯地平1和3 mg.kg-1对上述指标无明显影响。与正常对照组比较,模型组血清中铁含量由1.21±0.11升高到(1.57±0.25)mg.L-1,SF由232±17升高到(348±46)mg.L-1,锌、硒和钙含量分别由1.8±0.6,0.096±0.018和(120±26)mg.L-1降低到1.4±0.4,0.072±0.012和(77±15)mg.L-1(P<0.05,P<0.01),TIBC无明显变化;与模型组比较,硝苯地平5 mg.kg-1组血清铁含量降低到(1.32±0.14)mg.L-1,硒含量升高到(0.087±0.017)mg.L-1,钙含量升高到(97±16)mg.L-1(P<0.05),对SF,TIBC和锌含量无明显影响;硝苯地平1和3 mg.kg-1对上述指标无明显影响。结论硝苯地平能减少铁沉积,改善慢性铁过负荷大鼠的营养代谢,对铁过负荷等代谢疾病可能具有一定的治疗作用。     

阿伐他汀钙对老年脑梗死病人血脂水平及颈动脉粥样硬化的疗效

目的 探讨阿伐他汀钙对老年脑梗死病人血脂水平以及颈动脉粥样硬化的临床效果。方法 回顾性分析2015年2月至2016年2月驻马店市第四人民医院和驻马店市第一人民医院收治的急性脑梗死病人46例。按照治疗及随访期间是否服用阿伐他汀钙,将病人分为对照组及治疗组两组。对照组采用常规的抗血小板聚集以及对症支持治疗,治疗组在此基础上予以口服阿伐他汀钙,20 mg/d。对病人进行治疗随访,比较治疗前以及治疗半年后两组病人的血脂水平以及颈动脉内膜中层厚度以及内膜斑块的面积。结果 与治疗前比较,治疗组与对照组治疗半年后的三酰甘油,总胆固醇以及低密度脂蛋白(LDL),颈动脉内膜中层厚度显著降低,高密度脂蛋白(HDL)显著增高,差异有统计学意义(P<0.05);颈动脉斑块面积有所减少,但差异无统计学意义(P>0.05)。治疗半年后,治疗组的三酰甘油,总胆固醇以及低密度脂蛋白(LDL)[(1.2±0.2、3.8±0.4、2.4±0.3) mmol/L]低于对照组[(1.4±0.2、4.7±0.4、3.0±0.3) mmol/L],HDL[(1.4±0.3) mmol/L]显著高于对照组[(1.2±0.2) mmol/L],差异有统计学意义(P<0.05);颈动脉斑块厚度和面积[(1.3±0.2)mm、(22.1±9.0) mm²]与对照组[(1.5±0.5) mm、(26.2±10.0) mm²]比较均有所减少,差异有统计学意义(P<0.05)。结论 阿伐他汀钙能有效的降低老年急性脑梗死病人的血脂水平,减轻颈动脉内膜中层厚度,改善颈动脉粥样硬化的程度。     

重组人生长激素治疗肝硬化低清蛋白血症

目的:观察重组人生长激素(rhGH)治疗肝硬化引起的低清(白)蛋白血症的临床疗效。方法:选择血清清蛋白低于30g·L-1的肝硬化病人46例,男性39例,女性7例,分为治疗组、对照组各23例。治疗组在常规保肝及对症治疗基础上,给予rhGH,4IU,皮下注射,每日1次,连续14d;对照组仅给予常规保肝及对症治疗,14d为一个疗程。检测2组病人治疗前及治疗结束d1和4wk后血清清蛋白及其他肝功能指标变化,并进行临床观察。结果:治疗组治疗前血清清蛋白(25±s3)g·L-1,治疗结束d1血清清蛋白(31±3)g·L-1(P<0.01),4wk后血清清蛋白(33±3)g·L-1(P<0.01);对照组治疗前血清清蛋白(25±3)g·L-1,治疗结束d1血清清蛋白(25±3)g·L-1,4wk后血清清蛋白(24.4±2.6)g·L-1(P>0.05),2组治疗结束d1及4wk后血清清蛋白相比,差异有非常显著意义(P<0.01)。治疗结束d1及4wk内治疗组比对照组病人精神状态、食欲、尿量、腹腔积液、肝功能等均明显改善且持续稳定,有显著差异(P<0.05)。无明显不良反应。结论:rhGH可以增加肝硬化病人的血清清蛋白的水平,改善营养状况,无明显不良反应。     

降脂益肝冲剂治疗非酒精性脂肪性肝炎的实验研究

目的探讨降脂益肝冲剂对高脂饮食诱导的大鼠非酒精性脂肪性肝炎模型的影响。方法24只雄性Wistar大鼠随机分为3组(每组8只):正常组给予普通饲料喂养,模型组和治疗组给予高脂饮食喂养。治疗组在高脂饮食12w后给予降脂益肝冲剂,同时模型组和正常组分别给予等量的生活饮用水灌胃,18w末处死各组大鼠。测定空腹血糖(FBG)、空腹胰岛素(FINS),计算胰岛素敏感指数(ISI);测定血清丙氨酸氨基转移酶(ALT)、门冬氨酸氨基转移酶(AST)、总胆固醇(TC)、甘油三酯(TG),肝组织TC、TG、丙二醛(MDA)、超氧化物歧化酶(SOD)活性;HE染色观察肝组织病理变化。结果模型组大鼠血清转氨酶、血脂、肝组织TC、TG、MDA升高,SODI、SI降低,伴典型的脂肪性肝炎。模型组血清和肝组织TG、TC分别为(0.88±0.063)mmol/L和(1.20±0.04)mmol/L、TC分别为(3.81±0.57)mmol/L和(3.32±0.55)mmol/L;治疗组血清和肝组织TG、TC分别为(0.78±0.062)mmol/L和(0.52±0.05)mmol/L(、2.95±0.31)mmol/L和(1.63±0.20)mmol/L。模型组和治疗组ALT分别为(110.5±25.7)U.L-1和(77.5±16.1)U.L-1、AST分别为(273.5±27.5)U.L-1和(226.2±17.8)U.L-1,与模型组相比,治疗组的各项指标都有所改善,差异有统计学意义。结论降脂益肝冲剂能通过调节脂质代谢,改善胰岛素抵抗,对抗氧化应激和脂质过氧化损伤,降低肝脏的脂质沉积有效地治疗大鼠非酒精性脂肪性肝炎。     

粉防己碱对高血压心肌肥厚大鼠心肌胶原含量和肌球蛋白ATP酶活性的影响(英文)

观察粉防己碱对高血压心肌肥厚大鼠心肌胶原含量和肌球蛋白ATP酶活性的影响 .采用二肾一夹肾血管性高血压造成大鼠左心室肥厚模型 ,自术后第 9周起按粉防己碱 50mg·kg- 1,依那普利 6mg·g- 1灌胃给药 ,每日 1次 ,连续 8周 .用分光光度法测定心肌羟脯氨酸含量及肌球蛋白ATP酶活性 .结果表明左心室肥厚组心肌羟脯氨酸为 (5.9± 0 .3)mg·g- 1干重 ,明显高于假手术对照组〔(3.6± 0 .4 )mg·g- 1干重〕 ,粉防己碱组和依那普利组心肌羟脯氨酸含量分别较左心室肥厚组低 2 8.2 %和 39.0 % .左心室肥厚组肌球蛋白ATP酶活性仅为 (0 .4 3± 0 .0 9)mmolPi·min- 1·g- 1蛋白质 ,较假手术对照组〔(0 .97±0 .0 6 )mmolPi·min- 1·g- 1蛋白质〕明显降低 ,而粉防己碱组和依那普利组则分别比左心室肥厚组高 6 0 .5%和 118.6 % .实验结果表明粉防己碱可部分逆转肾血管性高血压所致的大鼠左心室肥厚 ,降低心肌胶原含量 ,升高肌球蛋白ATP酶活性     

基质金属蛋白酶-9在动脉粥样硬化血管中的异常表达

目的了解基质金属蛋白酶-9在Apo-E基因敲除小鼠的动脉粥样硬化斑块血管中的表达。方法 8只5周龄,雄性SPF级C57BL/6J小鼠为对照组(NS组)。8只相同周龄,雄性SPF级载脂蛋白E基因敲除(C57BL/6J-ApoE-/-)小鼠为实验组(FS组)。高脂(1%胆固醇+15%猪油)喂食15周,20周龄取材检测。结果 FS组和NS组体重分别为(29.10±2.53)g和(33.20±5.18)g,差异无统计学有意义(P>0.05)。FS组较NS组血清总胆固醇显著增高,分别为(13.52±1.58)mEq/L和(2.12±0.35)mEq/L,差异有统计学有意义(P<0.01)。NS组主动脉管壁正常,无AS斑块;FS组主动脉出现典型的AS斑块,胶原纤维明显减少。免疫组化显示NS组可见主动脉血管内、中膜MMP-9呈散在弱阳性表达;而其在FS组则是内膜表达明显增高,呈强阳性表达。FS组主动脉弓MMP-9在mRNA及蛋白水平的表达较NS组均明显增高。mRNA平均光密度值为(11.61±1.92)和(1.52±0.40),差异有统计学意义(P<0.05);蛋白平均光密度值为(190.40±102.71)和(40.19±26.83),差异有统计学有意义(P<0.01)。结论在高脂喂食的载脂蛋白E基因敲除小鼠动脉粥样硬化模型中,MMP-9高表达可能与动脉粥样硬化斑块的形成和胶原纤维明显减少有关。     

培哚普利对胰岛素抵抗的影响

目的 :研究培哚普利对胰岛素抵抗高血压大鼠胰岛素抵抗 (IR)的影响。方法 :选择雄性SD大鼠 30只分成 2组 ,对照组饲以基础饲料 ,培哚普利组饲以高糖高盐饲料 ,4wk后用培哚普利 0 .8mg·kg- 1·d- 1灌胃 4wk ,观察 2组实验前、4wk、8wk时收缩压 (SBP)、空腹血糖 (FBG )、空腹血胰岛素 (FINS)、胰岛素敏感性指数 (ISI)及红细胞膜Na ,K ATP酶活性测定的变化。结果 :培哚普利组 4wk时SBP升高 ,上升值为 (4 .4±s 1.6 )kPa ,FBG上升值 (0 .4± 0 .3)mmol·L- 1,FINS升高 (12 .7±2 .1) μU·L- 1,ISI降低 ,差值 1.30± 0 .2 0 ,红细胞膜Na ,K ATP酶活性降低 (12± 6 )nmoL·pi·mg- 1·pro·h- 1,P <0 .0 1。 8wk与 4wk时比较分别为 ,SBP[(13.2± 1.2 )kPavs (17.0± 2 .0 )kPa](P <0 .0 1) ,FBG分别为 [(2 .9± 0 .7)mmol·L- 1vs (3.8± 0 .3)mmol·L- 1](P <0 .0 1) ,FINS分别为 [(8.0± 1.5 ) μU·L- 1vs (18± 3) μU·L- 1](P <0 .0 1) ,ISI分别为 [(- 3.2 0± 0 .2 0 )vs (- 4.2 0± 0 .2 0 ) ](P <0 .0 1) ,红细胞膜Na ,K ATP酶活性分别为[(36± 9)nmoL·pi·mg- 1·pro·h- 1vs (2 6± 6 )nmoL·pi·mg- 1·pro·h- 1](P <0 .0 1)。结论 :培哚普利能改善高糖高盐饲养大鼠的IR。     

Efficacy of gut lavage,hemodialysis, and hemoperfusion in the therapy of paraquat or diquat intoxication

Clinical and in vitro investigations were carried out to test the efficacy of gut lavage, hemodialysis, and hemoperfusion in the treatment of poisoning with paraquat or diquat. In a patient suffering from diquat intoxication 130 times more diquat was removed by gut lavage 30 h after ingestion than was removed by complete aspiration of the gastric contents.Determination of in vitro clearances for paraquat and diquat by hemodialysis showed that, at serum concentrations of 1–2 ppm, such as are frequently encountered in poisoning in man, toxicologically relevant quantities of herbicide cannot be removed from the body. At a concentration of 20 ppm, on the other hand, hemodialysis proved to be effective, the clearance being 70 ml/min at a blood flow rate of 100 ml/min. The efficacy of hemoperfusion with coated activated charcoal was on the whole better. Especially at concentrations around 1–2 ppm, the clearance values for hemoperfusion were some 5–7 times higher than those for hemodialysis.In a patient suffering from paraquat poisoning, both hemodialysis as well as hemoperfusion were carried out. The in vitro results could be confirmed: At serum concentrations of paraquat less than 1 ppm no clearance could be obtained by hemodialysis while by hemoperfusion with activated charcoal quite high clearance values were measured and the serum level dropped down to zero.

---

Zusammenfassung Klinische Untersuchungen und Laboratoriumsversuche wurden durchgeführt, um die Wirksamkeit von Darmspülung, Hämodialyse und Hämoperfusion bei Paraquat- und Deiquat-Vergiftungen zu prüfen.Bei einem Patienten wurde 30 Std nach Deiquat-Aufnahme durch Darmspülung 130mal mehr Deiquat entfernt als durch vollständige Aspiration des Mageninhaltes. In vitro-Versuche ergaben, daß bei Blutserumkonzentrationen von 1–2 ppm, die bei Vergiftungen oft gemessen werden, durch Hämodialyse keine toxikologisch relevanten Paraquat- oder Deiquat-Mengen entfernt werden können. Dagegen erwies sich die Hämodialyse bei 20 ppm und einer Blutumlaufgeschwindigkeit von 100 ml/min mit einer Clearance von 70 ml/min als wirksam. Die Hämoperfusion mit beschicheter Aktivkohle war in diesen Versuchen aber eindeutig überlegen, denn insbesondere bei Konzentrationen um 1–2 ppm waren die Clearance-Werte 5–7mal höher als bei der Hämodialyse.Die in vitro-Ergebnisse wurden bei einem Patienten mit einer Paraquat-Vergiftung bestätigt: Bei Konzentrationen unter 1 ppm war die Hämodialyse wirkungslos, während durch Hämoperfusion relativ hohe Clearance-Werte erreicht wurden, so daß der Serumspiegel rasch unter die Nachweisgrenze abfiel.

     

In vitro studies on sterically stabilized liposomes (SL) as enzyme carriers in organophosphorus (OP) antagonism

This study describes a new approach for organophosphorous (OP) antidotal treatment by encapsulating an OP hydrolyzing enzyme, OPA anhydrolase (OPAA), within sterically stabilized liposomes. The recombinant OPAA enzyme was derived from Alteromonas strain JD6. It has broad substrate specificity to a wide range of OP compounds: DFP and the nerve agents, soman and sarin. Liposomes encapsulating OPAA (SL)* were made by mechanical dispersion method. Hydrolysis of DFP by (SL)* was measured by following an increase of fluoride ion concentration using a fluoride ion selective electrode. OPAA entrapped in the carrier liposomes rapidly hydrolyze DFP, with the rate of DFP hydrolysis directly proportional to the amount of (SL)* added to the solution. Liposomal carriers containing no enzyme did not hydrolyze DFP. The reaction was linear and the rate of hydrolysis was first order in the substrate. This enzyme carrier system serves as a biodegradable protective environment for the recombinant OP-metabolizing enzyme, OPAA, resulting in prolongation of enzymatic concentration in the body. These studies suggest that the protection of OP intoxication can be strikingly enhanced by adding OPAA encapsulated within (SL)* to pralidoxime and atropine.     

Aquatic Insects and Trace Metals: Bioavailability,Bioaccumulation, and Toxicity

Abstract

The uptake of metals from food and water sources by insects is thought to be additive. For a given metal, the proportions taken up from water and food will depend both on the bioavailable concentration of the metal associated with each source and the mechanism and rate by which the metal enters the insect. Attempts to correlate insect trace metal concentrations with the trophic level of insects should be made with a knowledge of the feeding relationships of the individual taxa concerned. Pathways for the uptake of essential metals, such as copper and zinc, exist at the cellular level, and other nonessential metals, such as cadmium, also appear to enter via these routes. Within cells, trace metals can be bound to proteins or stored in granules. The internal distribution of metals among body tissues is very heterogeneous, and distribution patterns tend to be both metal and taxon specific. Trace metals associated with insects can be both bound on the surface of their chitinous exoskeleton and incorporated into body tissues. The quantities of trace meals accumulated by an individual reflect the net balance between the rate of metal influx from both dissolved and particulate sources and the rate of metal efflux from the organism. The toxicity of metals has been demonstrated at all levels of biological organization: cell, tissue, individual, population, and community. Much of the literature pertaining to the toxic effects of metals on aquatic insects is based on laboratory observations and, as such, it is difficult to extrapolate the data to insects in nature. The few experimental studies in nature suggest that trace metal contaminants can affect both the distribution and the abundance of aquatic insects. Insects have a largely unexploited potential as biomonitors of metal contamination in nature. A better understanding of the physico-chemical and biological mechanisms mediating trace metal bioavailability and exchange will facilitate the development of general predictive models relating trace metal concentrations in insects to those in their environment. Such models will facilitate the use of insects as contaminant biomonitors.     

Pharmacological treatment of COVID-19: an opinion paper

The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.     

Alzheimer’s disease – current trends in basic and clinical research. Highlights from the 16th ECNP

Advances in the molecular biological knowledge of neuronal nicotinic acetylcholine receptors (nAChRs) have led to a growing interest by the pharmaceutical industry in the development of novel compounds that selectively modulate nAChR function. The ability of (-)-nicotine, an activator of nAChRs, to enhance attentional aspects of cognition in animals and humans, to exert neuroprotective and anxiolytic-like effects, and presumably to mediate the negative correlation between smoking and Alzheimer's (and Parkinson's) Disease, has focused interest on the potential therapeutic utility of modulators of nAChR function for treatment of some of the deficits associated with these progressive, neurodegenerative conditions. Numerous compounds are known which activate nAChRs and which might serve as lead compounds toward the development of such agents. The pharmacologic diversity of neuronal nAChR subtypes suggests the possibility of developing selective compounds which would have more favourable side-effect profiles than existing agents. This broader class of agents, collectively called cholinergic channel modulators (ChCMs), is anticipated to encompass compounds which would have more favourable side-effect profiles than existing agents, which generally exhibit low selectivity. This selectivity may be achieved by preferentially activating some subtypes of nAChRs (i.e., Cholinergic Channel Activators, ChCAs) or inhibiting the function of other subtypes (Cholinergic Channel Inhibitors, ChCIs). An overview of the biology of nAChRs and the rationale for the use of ChCMs for the treatment of dementia related to neurodegenerative diseases are presented, followed by a discussion of lead compounds and compounds under consideration for clinical evaluation.     

Steroidal sapogenin contents in some domestic plants

In order to find out the values of the steroid resources for the future use. the compositions and contents of steroidal sapogenins from 13 domestic plants have been investigated. As a result,Dioscorea nipponica, D. quinqueloba andSmilax china were found to have large amount of diosgenin. And pennogenin inTrillium kamtschaticum andParis verticillata, yuccagenin inAllium fistulosum, hecogenin inAgave americana and neochlorogenin inSolanum nigum were appeared to be major steroidal sapogenins.